The clinical course and therapy of mantle cell lymphoma (MCL) are heterogeneous and often unsatisfactory. Prognostic factors are needed to stratify the patients. Microvessel density (MVD) has prognostic significance in some malignancies. There is little information about the vasculature of MCL, although some antiangiogenic drugs are in use. We studied MVD using systematic uniform random sampling and unbiased counting frames in immunohistochemical reactions with anti-CD34 antibody in pre-therapeutic extramedullary MCL samples of 177 patients. We analyzed the relationship of MVD to overall survival (OS) and progression-free survival (PFS), as well as to proliferative activity (Ki-67), mantle cell lymphoma prognostic index (MIPI), morphological variant, pattern of growth, and localization. MVD varied widely: range 54.6-503.6 vessels/mm(2), median 158.2 vessels/mm(2). Higher MVD was associated with bone marrow infiltration at the time of diagnosis (P = 0.001). High MVD was associated with significantly worse OS (P = 0.04) only in patients treated with non-intensive (conventional) therapy. MVD correlated positively with MIPI scores but not with the proliferation, morphological variant, growth pattern, or localization. Univariate analysis identified a prognostic influence of morphological variant, MIPI, and proliferative activity on OS and PFS and a prognostic influence of bone marrow infiltration at the time of diagnosis on PFS. Multivariate analysis showed prognostic influence of MIPI and proliferative activity on OS and PFS only. In conclusion, this is the first clinicopathological study of MVD of MCL with long-term follow-up showing negative prognostic trends of high MVD in MCL and positive correlation of MVD and MIPI.

Sikl's Department of Pathology Faculty of Medicine in Pilsen Charles University Prague and University Hospital Pilsen Alej Svobody 80 304 60 Pilsen Czech Republic

See more in PubMed

N Engl J Med. 2012 Aug 9;367(6):520-31 PubMed

Blood. 2008 Jan 15;111(2):558-65 PubMed

Haematologica. 2012 Mar;97(3):416-22 PubMed

Eur J Cancer. 2010 Sep;46(13):2506-12 PubMed

J Hematop. 2009 Jul;2(2):103-11 PubMed

Br J Haematol. 2010 Jul;150(2):200-8 PubMed

Cancer Res. 2004 May 1;64(9):2941-55 PubMed

Bone Marrow Transplant. 2004 Aug;34(3):235-9 PubMed

Ann Oncol. 2010 Jan;21(1):133-9 PubMed

Lab Invest. 2008 Jan;88(1):38-47 PubMed

APMIS. 2001 Jan;109(1):66-72 PubMed

J Clin Pathol. 2004 Aug;57(8):856-60 PubMed

Microsc Res Tech. 2008 Oct;71(10):760-72 PubMed

Blood. 2010 Feb 25;115(8):1530-3 PubMed

Blood. 2008 Oct 1;112(7):2687-93 PubMed

Blood. 2008 Sep 15;112(6):2583; author reply 2583-4 PubMed

Haematologica. 2011 Jul;96(7):996-1001 PubMed

Leuk Lymphoma. 2014 Apr;55(4):802-10 PubMed

Res Vet Sci. 2008 Aug;85(1):56-61 PubMed

Ann Oncol. 2009 Mar;20(3):413-24 PubMed

Eur J Haematol. 2002 Jul;69(1):11-20 PubMed

Leuk Lymphoma. 1996 Mar;21(1-2):115-25 PubMed

Leukemia. 2004 Jul;18(7):1200-6 PubMed

Blood. 2008 Feb 15;111(4):2385-7 PubMed

Clin Cancer Res. 2005 Jan 1;11(1):154-61 PubMed

Cancer. 2010 Jun 1;116(11):2655-64 PubMed

Cancer Res. 2010 Feb 15;70(4):1408-18 PubMed

J Clin Oncol. 2014 May 1;32(13):1338-46 PubMed

Br J Haematol. 2005 Oct;131(1):29-38 PubMed

Prostate Cancer Prostatic Dis. 2002;5(2):123-7 PubMed

J Clin Pathol. 2007 May;60(5):476-82 PubMed

Cancer Sci. 2010 Mar;101(3):806-14 PubMed

Blood. 2006 Apr 15;107(8):3407 PubMed

Haematologica. 2010 Sep;95(9):1503-9 PubMed

Blood. 1997 Feb 15;89(4):1421-9 PubMed

J Hematol Oncol. 2010 Sep 09;3:30 PubMed

Histopathology. 2013 Oct;63(4):499-508 PubMed

Mod Pathol. 1996 Apr;9(4):361-6 PubMed

Blood. 1997 Mar 15;89(6):2067-78 PubMed

Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas

IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme